Sanofi: Soliqua Phase 3 results significantly lowered blood sugar levels compared to GLP-1 receptor agonist treatments
Soliqua Phase 3 results significantly lowered blood sugar levels compared to GLP-1 receptor agonist treatments Patients switched to Soliqua reached an average blood sugar below the American Diabet…
FinanzNachrichten.de: Meistgelesene Nachrichten
